GeoVax Labs

GOVX

Market cap $7.22M

0.1592 USD

-0.0809

33.69%

At close Updated Dec 19, 4:00 PM EST

Pre-market

After hours

0.1597

+0.0005

0.31%

1 day

-33.69%

5 days

-53.73%

1 month

-61.62%

3 months

-75.41%

6 months

-83.14%

Year to date

-93.58%

1 year

-93.14%

5 years

-99.67%

10 years

-99.64%

About: Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.

Employees: 17

Healthcare Biotechnology